Search

Your search keyword '"Hu, Jiafen"' showing total 192 results
Start Over Author "Hu, Jiafen"
192 results on '"Hu, Jiafen"'

1. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice

Author

Momenilandi, Mana, Lévy, Romain, Sobrino, Steicy, Li, Jingwei, Lagresle-Peyrou, Chantal, Esmaeilzadeh, Hossein, Fayand, Antoine, Le Floc’h, Corentin, Guérin, Antoine, Della Mina, Erika, Shearer, Debra, Delmonte, Ottavia M., Yatim, Ahmad, Mulder, Kevin, Mancini, Mathieu, Rinchai, Darawan, Denis, Adeline, Neehus, Anna-Lena, Balogh, Karla, Brendle, Sarah, Rokni-Zadeh, Hassan, Changi-Ashtiani, Majid, Seeleuthner, Yoann, Deswarte, Caroline, Bessot, Boris, Cremades, Cassandre, Materna, Marie, Cederholm, Axel, Ogishi, Masato, Philippot, Quentin, Beganovic, Omer, Ackermann, Mania, Wuyts, Margareta, Khan, Taushif, Fouéré, Sébastien, Herms, Florian, Chanal, Johan, Palterer, Boaz, Bruneau, Julie, Molina, Thierry J., Leclerc-Mercier, Stéphanie, Prétet, Jean-Luc, Youssefian, Leila, Vahidnezhad, Hassan, Parvaneh, Nima, Claeys, Kristl G., Schrijvers, Rik, Luka, Marine, Pérot, Philippe, Fourgeaud, Jacques, Nourrisson, Céline, Poirier, Philippe, Jouanguy, Emmanuelle, Boisson-Dupuis, Stéphanie, Bustamante, Jacinta, Notarangelo, Luigi D., Christensen, Neil, Landegren, Nils, Abel, Laurent, Marr, Nico, Six, Emmanuelle, Langlais, David, Waterboer, Tim, Ginhoux, Florent, Ma, Cindy S., Tangye, Stuart G., Meyts, Isabelle, Lachmann, Nico, Hu, Jiafen, Shahrooei, Mohammad, Bossuyt, Xavier, Casanova, Jean-Laurent, and Béziat, Vivien

Published
2024
Full Text
View/download PDF

2. Author Correction: The wide utility of rabbits as models of human diseases.

Author

Esteves, Pedro J, Abrantes, Joana, Baldauf, Hanna-Mari, BenMohamed, Lbachir, Chen, Yuxing, Christensen, Neil, González-Gallego, Javier, Giacani, Lorenzo, Hu, Jiafen, Kaplan, Gilla, Keppler, Oliver T, Knight, Katherine L, Kong, Xiang-Peng, Lanning, Dennis K, Le Pendu, Jacques, de Matos, Ana Lemos, Liu, Jia, Liu, Shuying, Lopes, Ana M, Lu, Shan, Lukehart, Sheila, Manabe, Yukari C, Neves, Fabiana, McFadden, Grant, Pan, Ruimin, Peng, Xuwen, de Sousa-Pereira, Patricia, Pinheiro, Ana, Rahman, Masmudur, Ruvoën-Clouet, Natalie, Subbian, Selvakumar, Tuñón, Maria Jesús, van der Loo, Wessel, Vaine, Michael, Via, Laura E, Wang, Shixia, and Mage, Rose

Subjects
Medicinal and Biomolecular Chemistry, Biochemistry & Molecular Biology
Abstract

This article was originally published under a CC BY-NC-SA License, but has now been made available under a CC BY 4.0 License.

Published
2019

3. The full transcription map of cottontail rabbit papillomavirus in tumor tissues.

Author

Jiang, Pengfei, Majerciak, Vladimir, Hu, Jiafen, Balogh, Karla, Meyer, Thomas J., Cam, Maggie, Shearer, Debra, Lanza, Matthew, Christensen, Neil, and Zheng, Zhi-Ming

Subjects
MOLECULAR biology, NUCLEIC acid hybridization, HUMAN papillomavirus, PAPILLOMAVIRUS diseases, ALTERNATIVE RNA splicing
Abstract

Cottontail rabbit papillomavirus (CRPV), the first papillomavirus associated with tumor development, has been used as a powerful model to study papillomavirus pathogenesis for more than 90 years. However, lack of a comprehensive analysis of the CRPV transcriptome has impeded the understanding of CRPV biology and molecular pathogenesis. Here, we report the construction of a complete CRPV transcription map from Hershey CRPV-induced skin tumor tissues. By using RNA-seq in combination with long-reads PacBio Iso-seq, 5′ and 3′ RACE, primer-walking RT-PCR, Northern blot, and RNA in situ hybridization, we demonstrated that the CRPV genome transcribes its early and late RNA transcripts unidirectionally from at least five distinct major promoters (P) and polyadenylates its transcripts at two major polyadenylation (pA) sites. The viral early transcripts are primarily transcribed from three "early" promoters, P90, P156, and P907 and polyadenylated at nt 4368 by using an early polyadenylation signal (PAS) at nt 4351. Like other low-risk human papillomaviruses and animal papillomaviruses, CRPV E6 and E7 transcripts are transcribed from three separate early promoters. Transcripts from two "late" promoters, P7525, and P1225, utilize either an early PAS for E1^E4 or a late PAS at 7399 for L2 and L1 RNA polyadenylation at nt 7415 to express capsid L2 and L1 proteins respectively. By using the mapped four 5′ splice sites and three 3′ splice sites, CRPV RNA transcripts undergo extensive alternative splicing to produce more than 33 viral RNA isoforms for production of at least 12 viral proteins, some of which without codon optimization are expressible in rabbit RK13 and human HEK293T cells. The constructed full CRPV transcription map in this study for the first time will enhance our understanding of the structures and expressions of CRPV genes and their contribution to molecular pathogenesis and tumorigenesis. Author summary: Papillomavirus infections induce benign warts and cancers. Naturally occurring infections in animal models have played a pivotal role in studying human papillomavirus pathogenesis. The cottontail rabbit papillomavirus (CRPV), the first reported papillomavirus, has been used widely for understanding the pathogenesis of papillomavirus-associated diseases and cancer. The current study uses the state-of-the-art RNA-seq and PacBio Iso-seq in combination with 5′ and 3′ RACE, primer-walking RT-PCR, Northern blot, and RNA in situ hybridization to determine genome-wide transcription and RNA structures of individual CRPV transcripts in Hershey CRPV-induced rabbit skin wart tissues. As a result, we have constructed the full transcription map from CRPV-induced rabbit skin warts and further determined the relative abundance and spatial localization of identified viral transcripts in these warts. The CRPV genome uses three early and two late viral promoters, four splice donor and three splice acceptor sites, and two viral PAS to express at least 33 RNA isoforms and twelve viral proteins. Most of their open reading frames were cloned for ectopic expression in this study. The constructed CRPV transcript map in this report will provide an important resource to advance our understanding of papillomavirus biology and pathogenesis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. The wide utility of rabbits as models of human diseases.

Author

Esteves, Pedro J, Abrantes, Joana, Baldauf, Hanna-Mari, BenMohamed, Lbachir, Chen, Yuxing, Christensen, Neil, González-Gallego, Javier, Giacani, Lorenzo, Hu, Jiafen, Kaplan, Gilla, Keppler, Oliver T, Knight, Katherine L, Kong, Xiang-Peng, Lanning, Dennis K, Le Pendu, Jacques, de Matos, Ana Lemos, Liu, Jia, Liu, Shuying, Lopes, Ana M, Lu, Shan, Lukehart, Sheila, Manabe, Yukari C, Neves, Fabiana, McFadden, Grant, Pan, Ruimin, Peng, Xuwen, de Sousa-Pereira, Patricia, Pinheiro, Ana, Rahman, Masmudur, Ruvoën-Clouet, Natalie, Subbian, Selvakumar, Tuñón, Maria Jesús, van der Loo, Wessel, Vaine, Michael, Via, Laura E, Wang, Shixia, and Mage, Rose

Subjects
Animals, Biological Evolution, Disease Models, Animal, Humans, Immune System: physiology, Immunity, Rabbits
Abstract

Studies using the European rabbit Oryctolagus cuniculus contributed to elucidating numerous fundamental aspects of antibody structure and diversification mechanisms and continue to be valuable for the development and testing of therapeutic humanized polyclonal and monoclonal antibodies. Additionally, during the last two decades, the use of the European rabbit as an animal model has been increasingly extended to many human diseases. This review documents the continuing wide utility of the rabbit as a reliable disease model for development of therapeutics and vaccines and studies of the cellular and molecular mechanisms underlying many human diseases. Examples include syphilis, tuberculosis, HIV-AIDS, acute hepatic failure and diseases caused by noroviruses, ocular herpes, and papillomaviruses. The use of rabbits for vaccine development studies, which began with Louis Pasteur's rabies vaccine in 1881, continues today with targets that include the potentially blinding HSV-1 virus infection and HIV-AIDS. Additionally, two highly fatal viral diseases, rabbit hemorrhagic disease and myxomatosis, affect the European rabbit and provide unique models to understand co-evolution between a vertebrate host and viral pathogens.

Published
2018

5. Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome:A systematic review

Author

Fobian, Seth Frerich, Mei, Xionge, Crezee, Johannes, Snoek, Barbara C., Steenbergen, Renske D.M., Hu, Jiafen, ten Hagen, Timo L.M., Vermeulen, Louis, Stalpers, Lukas J.A., Oei, Arlene L., Fobian, Seth Frerich, Mei, Xionge, Crezee, Johannes, Snoek, Barbara C., Steenbergen, Renske D.M., Hu, Jiafen, ten Hagen, Timo L.M., Vermeulen, Louis, Stalpers, Lukas J.A., and Oei, Arlene L.

Abstract

Cervical cancer is the fourth most common cancer in women worldwide and is caused by persistent infection with high-risk types of human papillomavirus (HPV). HPV viral load, the amount of HPV DNA in a sample, has been suggested to correlate with cervical disease severity, and with clinical outcome of cervical cancer. In this systematic review, we searched three databases (EMBASE, PubMed, Web of Science) to examine the current evidence on the association between HPV viral load in cervical samples and disease severity, as well as clinical outcome. After exclusion of articles not on HPV, cervical cancer, or containing clinical outcomes, 85 original studies involving 173 746 women were included. The vast majority (73/85 = 85.9%) reported that a higher viral load was correlated with higher disease severity or worse clinical outcome. Several studies reported either no correlation (3/85 = 3.5%), or the opposite correlation (9/85 = 10.6%); possible reasons being different categorization of HPV viral load levels, or the use of specific sampling methods. Despite variations in study design and populations, the above findings suggest that HPV viral load is correlated to clinical outcome, and may become an important biomarker for treatment selection and response monitoring for cervical cancer.

Published
2024

6. Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: A systematic review.

Author

Fobian, Seth‐Frerich, Mei, Xionge, Crezee, Johannes, Snoek, Barbara C., Steenbergen, Renske D. M., Hu, Jiafen, ten Hagen, Timo L. M., Vermeulen, Louis, Stalpers, Lukas J. A., and Oei, Arlene L.

Subjects
HUMAN papillomavirus, TREATMENT effectiveness, VIRAL load, GENITAL warts, CERVICAL cancer, CANCER patients
Abstract

Cervical cancer is the fourth most common cancer in women worldwide and is caused by persistent infection with high‐risk types of human papillomavirus (HPV). HPV viral load, the amount of HPV DNA in a sample, has been suggested to correlate with cervical disease severity, and with clinical outcome of cervical cancer. In this systematic review, we searched three databases (EMBASE, PubMed, Web of Science) to examine the current evidence on the association between HPV viral load in cervical samples and disease severity, as well as clinical outcome. After exclusion of articles not on HPV, cervical cancer, or containing clinical outcomes, 85 original studies involving 173 746 women were included. The vast majority (73/85 = 85.9%) reported that a higher viral load was correlated with higher disease severity or worse clinical outcome. Several studies reported either no correlation (3/85 = 3.5%), or the opposite correlation (9/85 = 10.6%); possible reasons being different categorization of HPV viral load levels, or the use of specific sampling methods. Despite variations in study design and populations, the above findings suggest that HPV viral load is correlated to clinical outcome, and may become an important biomarker for treatment selection and response monitoring for cervical cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Gender Difference in DNA Damage Induced by the Environmental Carcinogen Dibenzo[def,p]chrysene Individually and in Combination with Mouse Papillomavirus Infection in the Mouse Oral Cavity

Author

Chen, Kun-Ming, primary, Sun, Yuan-Wan, additional, Hu, Jiafen, additional, Balogh, Karla, additional, Gowda, Krishne, additional, Aliaga, Cesar, additional, Sun, Dongxiao, additional, Christensen, Neil, additional, Amin, Shantu, additional, and El-Bayoumy, Karam, additional

Published
2024
Full Text
View/download PDF

12. DNA Vaccines: Their Formulations, Engineering and Delivery.

Author

Kozak, Michael and Hu, Jiafen

Subjects
DNA vaccines, VACCINE immunogenicity, COVID-19 vaccines, HUMAN DNA, VETERINARY medicine, MATERNALLY acquired immunity, SPORTS sciences
Abstract

The concept of DNA vaccination was introduced in the early 1990s. Since then, advancements in the augmentation of the immunogenicity of DNA vaccines have brought this technology to the market, especially in veterinary medicine, to prevent many diseases. Along with the successful COVID mRNA vaccines, the first DNA vaccine for human use, the Indian ZyCovD vaccine against SARS-CoV-2, was approved in 2021. In the current review, we first give an overview of the DNA vaccine focusing on the science, including adjuvants and delivery methods. We then cover some of the emerging science in the field of DNA vaccines, notably efforts to optimize delivery systems, better engineer delivery apparatuses, identify optimal delivery sites, personalize cancer immunotherapy through DNA vaccination, enhance adjuvant science through gene adjuvants, enhance off-target and heritable immunity through epigenetic modification, and predict epitopes with bioinformatic approaches. We also discuss the major limitations of DNA vaccines and we aim to address many theoretical concerns. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections

Author

Brendle, Sarah A., primary, Li, Jingwei, additional, Cladel, Nancy M., additional, Balogh, Karla K., additional, Booth, Jennifer, additional, Shearer, Debra A., additional, Walter, Vonn, additional, Lu, Song, additional, Christensen, Neil D., additional, Covington, Danielle, additional, DeBroff, Jake, additional, Milici, Janice, additional, Zhu, Yusheng, additional, Viscidi, Raphael, additional, and Hu, Jiafen, additional

Published
2022
Full Text
View/download PDF

23. Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal Tissues

Author

Brendle, Sarah, primary, Li, Jingwei J., additional, Cladel, Nancy M., additional, Shearer, Debra A., additional, Budgeon, Lynn R., additional, Balogh, Karla K., additional, Atkins, Hannah, additional, Costa-Fujishima, Marina, additional, Lopez, Paul, additional, Christensen, Neil D., additional, Doorbar, John, additional, Murooka, Thomas T., additional, and Hu, Jiafen, additional

Published
2021
Full Text
View/download PDF

25. Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy

Author

Béziat, Vivien, primary, Rapaport, Franck, additional, Hu, Jiafen, additional, Titeux, Matthias, additional, Bonnet des Claustres, Mathilde, additional, Bourgey, Mathieu, additional, Griffin, Heather, additional, Bandet, Élise, additional, Ma, Cindy S., additional, Sherkat, Roya, additional, Rokni-Zadeh, Hassan, additional, Louis, David M., additional, Changi-Ashtiani, Majid, additional, Delmonte, Ottavia M., additional, Fukushima, Toshiaki, additional, Habib, Tanwir, additional, Guennoun, Andrea, additional, Khan, Taushif, additional, Bender, Noemi, additional, Rahman, Mahbuba, additional, About, Frédégonde, additional, Yang, Rui, additional, Rao, Geetha, additional, Rouzaud, Claire, additional, Li, Jingwei, additional, Shearer, Debra, additional, Balogh, Karla, additional, Al Ali, Fatima, additional, Ata, Manar, additional, Dabiri, Soroosh, additional, Momenilandi, Mana, additional, Nammour, Justine, additional, Alyanakian, Marie-Alexandra, additional, Leruez-Ville, Marianne, additional, Guenat, David, additional, Materna, Marie, additional, Marcot, Léa, additional, Vladikine, Natasha, additional, Soret, Christine, additional, Vahidnezhad, Hassan, additional, Youssefian, Leila, additional, Saeidian, Amir Hossein, additional, Uitto, Jouni, additional, Catherinot, Émilie, additional, Navabi, Shadi Sadat, additional, Zarhrate, Mohammed, additional, Woodley, David T., additional, Jeljeli, Mohamed, additional, Abraham, Thomas, additional, Belkaya, Serkan, additional, Lorenzo, Lazaro, additional, Rosain, Jérémie, additional, Bayat, Mousa, additional, Lanternier, Fanny, additional, Lortholary, Olivier, additional, Zakavi, Faramarz, additional, Gros, Philippe, additional, Orth, Gérard, additional, Abel, Laurent, additional, Prétet, Jean-Luc, additional, Fraitag, Sylvie, additional, Jouanguy, Emmanuelle, additional, Davis, Mark M., additional, Tangye, Stuart G., additional, Notarangelo, Luigi D., additional, Marr, Nico, additional, Waterboer, Tim, additional, Langlais, David, additional, Doorbar, John, additional, Hovnanian, Alain, additional, Christensen, Neil, additional, Bossuyt, Xavier, additional, Shahrooei, Mohammad, additional, and Casanova, Jean-Laurent, additional

Published
2021
Full Text
View/download PDF

29. The environmental pollutant and tobacco smoke constituent dibenzo[def,p]chrysene is a co-factor for malignant progression of mouse oral papillomavirus infections

Author

Christensen, Neil D., primary, Chen, Kun-Ming, additional, Hu, Jiafen, additional, Stairs, Douglas B., additional, Sun, Yuan-Wan, additional, Aliaga, Cesar, additional, Balogh, Karla K., additional, Atkins, Hannah, additional, Shearer, Debra, additional, Li, Jingwei, additional, Brendle, Sarah A., additional, Gowda, Krishne, additional, Amin, Shantu, additional, Walter, Vonn, additional, Viscidi, Raphael, additional, and El-Bayoumy, Karam, additional

Published
2021
Full Text
View/download PDF

33. Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model

Author

Hu, Jiafen, primary, Balogh, Karla, additional, Matsui, Ken, additional, Tan, Huimin, additional, Olczak, Pola, additional, Buchman, George, additional, Howard, Brian, additional, White, Jonathan, additional, Kennedy, Michelle, additional, Sei, Shizuko, additional, Glaze, Elizabeth, additional, Brendle, Sarah, additional, Schellenbacher, Christina, additional, Kirnbauer, Reinhard, additional, Roden, Richard, additional, Shoemaker, Robert, additional, Christensen, Neil, additional, and Wang, Joshua Weiyuan, additional

Published
2019
Full Text
View/download PDF

34. Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models

Author

Cladel, Nancy M., primary, Jiang, Pengfei, additional, Li, Jingwei J., additional, Peng, Xuwen, additional, Cooper, Timothy K., additional, Majerciak, Vladimir, additional, Balogh, Karla K., additional, Meyer, Thomas J., additional, Brendle, Sarah A., additional, Budgeon, Lynn R., additional, Shearer, Debra A., additional, Munden, Regina, additional, Cam, Maggie, additional, Vallur, Raghavan, additional, Christensen, Neil D., additional, Zheng, Zhi-Ming, additional, and Hu, Jiafen, additional

Published
2019
Full Text
View/download PDF

48. A Novel HLA (HLA-A*0201) Transgenic Rabbit Model for Preclinical Evaluation of Human CD8+ T Cell Epitope-Based Vaccines against Ocular Herpes

Author

Chentoufi, Aziz A., primary, Dasgupta, Gargi, additional, Christensen, Neil D., additional, Hu, Jiafen, additional, Choudhury, Zareen S., additional, Azeem, Arfan, additional, Jester, James V., additional, Nesburn, Anthony B., additional, Wechsler, Steven L., additional, and BenMohamed, Lbachir, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results